Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak

Core Viewpoint - Theratechnologies Inc. has received shareholder approval for a plan of arrangement involving CB Biotechnology, LLC, an affiliate of Future Pak, LLC, under the Business Corporations Act (Québec) [1][2]. Group 1: Shareholder Approval - The arrangement resolution was approved by 97.44% of the votes cast by shareholders present in person or virtually, and by 97.43% when excluding certain votes as required by Multilateral Instrument 61-101 [2]. Group 2: Next Steps - The proposed arrangement is subject to customary closing conditions, including the issuance of a final order by the Superior Court of Québec, with a hearing scheduled for September 16, 2025 [3]. Group 3: Company Background - Theratechnologies is a specialty biopharmaceutical company focused on the commercialization of innovative therapies aimed at redefining standards of care [4]. - Future Pak, founded in 1977, is a privately held contract manufacturer, packager, and distributor of pharmaceutical and nutraceutical products, operating across various markets [5].